Relationship between TIMI frame count and clinical outcomes after thrombolytic administration

Circulation

Volumn 99, Issue 15, 1999, Pages 1945-1950

  Gibson, C Michael ^a   Murphy, Sabina A ^a   Rizzo, Michael J ^a   Ryan, Kathryn A ^a   Marble, Susan J ^a   McCabe, Carolyn H ^c   Cannon, Christopher P ^c   Van De Werf, Frans ^b   Braunwald, Eugene ^c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood flow; Myocardial infarction; Thrombolysis; TIMI frame count

Indexed keywords

ALTEPLASE; ANISTREPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033586683     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.15.1945     Document Type: Article

References (16)

1. The TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial. N Engl J Med, 1985;31:932-936.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
3. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
4. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1989;1:1367-1369.
5. Vogt A, Von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993; 21:1391-1395.
6. Karagounis L, Sorensen SG, Menlove RI, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction TIMI perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol. 1992;17:1-10.
7. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation. 1993;87:1829-1839.
8. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. The TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
9. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri S, Davis V, Gibson CM, Poole WK, Braunwald E, for the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994;24:1602-1610.
10. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E, and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351-356.
11. Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Fox NL, Weaver WD, Van de Werf F, Braunwald E, for the TIMI 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B Trial. Circulation. 1998;98:2805-2814.
12. Stata Corp. Stata Statistical Software: Release 5.0. College Station, Tex: Stata Corp; 1997.
13. Gibson CM, Goel M, Cohen DE, Piana RN, Deckelbaum LI, Harris KE, King SB, for the RESTORE Investigators. Six month angiographic and clinical outcomes following IIb/IIIa blockade with tirofiban. J Am Coll Cardiol. 1998;32:28-34.
14. Gibson CM, Goel M, Dotani I, Rizzo MJ, McLean C, Martin NE, Al-Mousa EN, Marble SJ, Daley WL, Dodge T. The post-PTCA TIMI frame count and mortality in RESTORE. Circulation. 1996;94(suppl I):I-85. Abstract.
15. Lee KL, Woodlief LH, Topol EJ, Weaver DW, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Maliff RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
16. Gibson M, Giugliano RP, Anderson K, Scherer JC, McCabe CH, Antman EM. Abciximab enhances thrombolysis. a comparison of abciximab alone versus abciximab plus low dose thrombolytics using the corrected TIMI frame count. Circulation. 1998;98(suppl):I-559. Abstract.